# US 2024/0189225 A1 · Compositions and methods for hardening

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189225 A1
- Document ID: US20240189225A1
- Status: Published application
- Kind: A1
- Application number: 17/998,689
- Filed: 2021-05-14
- Published: 2024-06-13
- Earliest claimed: 2020-05-15
- Assignees: SPI Pharma, Inc.
- Applicants: SPI Pharma, Inc.
- Inventors: Brian Wilson; Greg Simon; Graeme Macleod
- Web page: https://patentgrep.com/patent/US20240189225A1

## CPC

- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 9/2095: {Tabletting processes}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2893: {Tablet coating processes (mechanical aspects A61J3/06)}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 9/5042: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
- A61K 9/5078: {with drug-free core}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 9/0007: {Effervescent (A61K9/0065 takes precedence)}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to, among other things, compositions and methods for improving hardness without using excessive compression forces, thereby preserving compression-sensitive or pressure-sensitive active ingredients. The present disclosure also relates to compositions and methods for preparing post-compression hardening materials having a high tensile strength at low water activity.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A dose form selected from a chewable, a tablet, a minitablet, a wafer, a compact, a lozenge, a granule, a hard capsule plug, an effervescent, and a ribbon, wherein the dose form comprises an excipient system comprising two or more polyols, and one or more other excipients selected from the group consisting of sodium stearyl fumarate, magnesium stearate, micro crystalline cellulose, dicalcium phosphate, cellulose, hydroxypropyl cellulose, colloidal silica, fumed silica, PEG, talc, flavors, colors, calcium carbonate, cyclodextrin, gelatin, cellulose ethers, sweeteners, stearic acid, citric acid, hydrogenated castor oil, glyceryl monostearate, methylcellulose, polysorbate, titanium dioxide, starch, a super disintegrant, alginate, lactose, maltose, sucrose, glucose, polydextrose, dextrose, and PVP, wherein upon further processing or storage, a hardness value of the dose form increases by at least 50%.

### Claim 24 (depends on 23)

The dose form of claim 23, further comprising one or more of an active pharmaceutical ingredient, a nutraceutical ingredient, a veterinary product, a probiotic, a detergent, a pressure sensitive component, and/or a food supplement.

### Claim 25 (depends on 23)

The dose form of claim 23, wherein the dose form weighs in the range of about 10 mg to about 4500 mg.

### Claim 26

(canceled)

### Claim 27 (depends on 23)

The dose form of claim 23, wherein the dose form has a moisture content determined by water activity to be about 0.0225 to about 0.4 and/or a moisture content determined by loss on drying or Karl Fischer titration to be about 0.05% to about 5.0%.

### Claim 28

(canceled)

### Claim 29 (depends on 23)

The dose form of claim 23, wherein, upon further processing or storage, the dose form has a moisture content determined by water activity to be about 0.01 to about 0.5 or determined by loss on drying or Karl Fischer titration to be about 0.05% to about 5.0%.

### Claim at position 9

30-31. (canceled)

### Claim 32 (depends on 23)

The dose form of claim 23, wherein the dose form has a hardness of about 0.6 kilopond (kP) to about 30 kP and/or a friability of about 0.05% to about 5%.

### Claim 33

(canceled)

### Claim 34 (depends on 23)

The dose form of claim 23, wherein, upon storage or further processing, a hardness of the dose form is between about 1.6 kilopond (kP) and about 50 kP.

### Claim 35 (depends on 23)

The dose form of claim 23, wherein the two or more polyols comprise mannitol, sorbitol, and maltitol.

### Claim 36 (depends on 35)

The dose form of claim 35, wherein the ratio of mannitol:sorbitol:maltitol is about 80:10:10 by weight or about 70:20:10 by weight.

### Claim 37

(canceled)

### Claim 38 (depends on 24)

The dose form of claim 24, wherein:
the probiotic CFU is in the range of 100% of the intended label claim prior to compaction, which following initial compaction the probiotic CFU count decreases by less than between about 0.1% to about 50%;
the probiotic loading is in the range of between about 0.1% to about 50% by weight of the finished dosage form, wherein the CFU count following further processing or storage is about the same; or
upon further processing or storage the hardness of the dose form increases by at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 110%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 160%, at least about 170%, at least about 180%, at least about 190%, at least about 200%, at least about 210%, at least about 220%, at least about 230%, at least about 240%, or at least about 250%, at least about 300%, at least about 350%, or at least about 400%.

### Claim at position 17

39-41. (canceled)

### Claim 42 (depends on 24)

The dose form of claim 24, wherein the pressure sensitive component is a controlled release or taste masked pellet, granule, core, or particle containing an active pharmaceutical, an ingredient, a nutraceutical ingredient, a veterinary ingredient, a probiotic, a vitamin, a detergent or a food supplement; or wherein the active pharmaceutical ingredient is aspirin, paracetamol, ibuprofen, diclofenac, naproxen, guaiphenesin, loratadine, dextromethorphan, pseudoephedrine, famotidine, cetirizine, nicotine, amlodipine, sildenafil, ondansetron, loperamide, tadalafil, benzodiazepine, clopidogrel, fenofibrate, cannabidiol, isosorbide mononitrate, levothyroxine, lisinopril, losartan, lovastatin, metformin, montelukast, omeprazole, paroxetine, prednisolone, simvastatin, venlafaxine, or zolpidem.

### Claim at position 19

43-47. (canceled)

### Claim 48

A solid dosage form, comprising:
(i) two or more polyols co-processed to form a homogeneous material, wherein the two or more polyols are independently selected from the group consisting of mannitol, sorbitol, maltitol, xylitol, erythritol, hydrogenated starch hydrolysates, isomalt, and lactitol, wherein the two or more polyols comprises a first polyol present in an amount of about 5 wt % to about 25 wt %, and a second polyol present in an amount of 5 wt % to 25 wt %; and
(ii) one or more compression-sensitive or pressure-sensitive active ingredients,
wherein (1) a hardness (in kiloponds, kP) of the solid dosage form per compression force (in kilonewtons, kN) used to form the solid dosage form is at least about 2.0 after less than about 24 hours of storage, and/or (2) the solid dosage form comprises a first hardness at time t0 and a second hardness at time t1 that is at least about 50% greater than the first hardness, wherein the time t1 is about 4 hours, about 8 hours, about 12 hours, about 16 hours, about 20 hours, or about 24 hours after the time t0.

### Claim 49 (depends on 48)

The solid dosage form of claim 48, wherein the solid dosage form comprises a water activity (Aw) of less than about 0.7, less than about 0.6, less than about 0.5, less than about 0.4, less than about 0.3, less than about 0.2, less than about 0.1, less than about 0.05, or less than about 0.01.

### Claim 50 (depends on 48)

The solid dosage form of claim 48, wherein the hardness (in kP) of the solid dosage form per compression force (in kN) used to form the solid dosage form is at least about at least about 1.0 kP/kN, at least about 1.5 kP/kN, at least about 2.0 kP/kN, at least about 2.5 kP/kN, at least about 3.0 kP/kN, at least about 3.5 kP/kN, at least about 4.0 kP/kN, at least about 4.5 kP/kN, at least about 5.0 kP/kN, at least about 6 kP/kN, at least about 7 kP/kN, at least about 8 kP/kN, at least about 9 kP/kN, or at least about 10 kP/kN after less than about 24 hours, less than about 12 hours, or less than about 6 hours of storage.

### Claim at position 23

51-52. (canceled)

### Claim 53 (depends on 48)

The solid dosage form of claim 48, wherein the one or more compression-sensitive or pressure-sensitive active ingredients is independently selected from the group consisting of an active pharmaceutical ingredient, a nutraceutical ingredient, a veterinary product, a probiotic, a detergent, and a food supplement.

### Claim 54

(canceled)

### Claim 55 (depends on 48)

The solid dosage form of claim 48, wherein the ratio of the first polyol to the second polyol is about 1:1, about 2:1, or about 1:2.

### Claim at position 27

56-62. (canceled)

### Claim 63 (depends on 48)

The solid dosage form of claim 48, wherein the solid dosage form is a chewable, a swallow tablet, a wafer, a compact, a ribbon, an orally disintegrating tablet (ODT), a lozenge, a fast melt, a bi-layer, a tri-layer, a minitablet, a granule, a hard capsule plug, or an effervescent.

### Claim 64 (depends on 48)

The solid dosage form of claim 48, further comprising one or more excipients independently selected from the group consisting of sodium stearyl fumarate, magnesium stearate, micro crystalline cellulose, starch, a super disintegrant, alginate, lactose, maltose, sucrose, glucose, polydextrose, dextrose, and PVP.

### Claim 65 (depends on 48)

The solid dosage form of claim 48, wherein the two or more polyols comprise mannitol, sorbitol, and maltitol.

### Claim 66 (depends on 65)

The solid dosage form of claim 65, wherein the ratio of mannitol:sorbitol:maltitol is about 80:10:10 by weight or about 70:20:10 by weight.

### Claim at position 32

67-96. (canceled)
